We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current 0Y5F market cap is 1.4B. The company's latest EPS is USD -10.4150 and P/E is -0.03.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 2.96B | 2.92B | 3B | 2.32B | 2.01B |
| Operating Income | 88.33M | 487.47M | 51.43M | -2.37B | -2.4B |
| Net Income | -422.64M | 183.94M | -613.25M | -2.92B | -2.45B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 9.39B | 9.26B | 8.77B | 5.76B | 5.14B |
| Total Liabilities | 10.26B | 9.91B | 10.01B | 9.92B | 11.73B |
| Total Equity | -866.54M | -647.94M | -1.24B | -4.16B | -6.6B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 98.05M | 397.39M | 411.05M | 269.19M | 435.1M |
| Investing | -60.2M | -624.87M | -59.54M | -133.15M | -49.79M |
| Financing | 204.6M | -108.57M | -105.48M | -513.87M | -604.63M |
| Market Cap | 1.4B |
| Price to Earnings Ratio | -0.03 |
| Price to Sales Ratio | 0.03 |
| Price to Cash Ratio | 0.09 |
| Price to Book Ratio | -0.01 |
| Dividend Yield | - |
| Shares Outstanding | 235.22M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 0.00% |
| 52 Week High | 5.97 |
| 52 Week Low | 5.97 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Endo International Plc |
| Address |
first floor dublin 4 |
| Website | https://www.endo.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
